224 Studies Now Enrolling
Menu
Search
Status
Medical Condition
- Show all (1219)
- Addiction (16)
- Allergy, Asthma, & Immunology (12)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (28)
- Blood Disorders (18)
- Bone & Muscle (10)
- Cancer (101)
- Child Development (4)
- COVID-19 (Coronavirus) (36)
- Critical Illness (1)
- Diabetes (21)
- Ear, Nose and Throat (12)
- Endocrine & Metabolic Disease (12)
- Eye (7)
- Gastrointestinal and Digestive Diseases (26)
- Hair and Skin Disorders (3)
- Headaches (5)
- Healthy Volunteers (187)
- Heart Disease (130)
- Infectious Disease (48)
- Insomnia (3)
- Kidney Disease (12)
- Liver Disease (52)
- Lung Disease (31)
- Meniere's Disease (1)
- Neurological Disorders (126)
- Nutrition (5)
- Obesity (9)
- Obstetrics & Gynecology (55)
- Pain Management (1)
- Pediatrics (98)
- Psychiatric Disorders (67)
- Rehabilitation (9)
- Stroke (7)
- Surgery (7)
- Transplant (45)
- Urology (3)
- Vascular Conditions (10)
Displaying 1 - 3 of 3
Condition: Skin Cancer / Melanoma
Investigator: Larisa Geskin, MD
Status: Closed
The purpose of this study is to determine how effective and safe the immune drug Nivolumab is for patients who have newly diagnosed cutaneous melanoma. Nivolumab is an anti-body, a type of human protein, that is being tested to see if it will allow the body's immune system to work against tumor cells. If you are eligible for the study, you will…
Condition: Lung Disease / Chronic Obstructive Lung Disease
Investigator: Anna Norweg, OTR
Status: Closed
Capnography-Assisted, Learned, Monitored (CALM) Breathing is a mind-body intervention for COPD that uses breathing exercises and biofeedback with the goal of reducing shortness of breath, anxiety symptoms and improving overall quality of life. The intervention is a 4-week (1 hour, twice weekly) program taking place in-person at New York Presbyterian…
Condition: Vascular Conditions / Vasculitis
Investigator: Andrew Bomback, MD
Status: Closed
The purpose of this study is to evaluate the safety and tolerability of study drug CCX168 when it is given to patients who are receiving the standard therapy for a certain type of vasculitis called ANCA-associated vasculitis (AAV). The study will also assess the effectiveness of the study drug, CCX168, in combination with the standard treatment of AAV. This…